Translational Medicine: from Bench to Bedside
Date: Wednesday, October 12, 2011
Confirmed speakers:
Tom Clement, President & CEO, Aqueduct
Tom Fritz, President & CEO, Inland Northwest Health Services
Mike Gallatin, Former President, Calistoga; former Executive, Icos
Jeffrey Herz, President & Founder, Algomedix
Gary Jones, MD, Chief Medical Officer and Director of Clinical Development, C3 Research Associates
Translational Medicine is the process of turning biological discoveries into drugs and/or medical devices that can help patients better, faster, and cheaper. In the case of drug discovery and development, translational research typically refers to the translation of laboratory-based research into therapies for patients. In the case of medical devices, translational process focuses on the translation of problems observed at bedside into device therapies for patients. This may be couched at “bedside to bench” definition.
In this program we will discuss formation of a company, manufacturability, regulatory, and reimbursement strategies all within the context of translational medicine.
Registration Fees:
WBBA Member- $35.00
Non-Member- $50.00
Academia, Nonprofit, Student- $25.00
Time: 7:00 – 10:30 AM
Registration 7AM; Program and Panel 7:30-10:30 AM
Location: University of Washington Center for Urban Horticulture, 3501 NE 41st Street, Seattle, WA 98195
